SCHEMBL29839276

SCHEMBL29839276

Cc1cn(C)c(=O)c2c(C(=O)N3CC4CC4(c4cccc(Cl)c4)C3)cn(C)c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 5/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ HPGD P15428 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ CNR1 P21554 1/20 0.37
▸ CNR2 P34972 1/20 0.37
▸ LMNA P02545 2/20 0.36
▸ ABL1 P00519 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ RIN1 Q13671 1/20 0.36
▸ DRD2 P14416 1/20 0.34
▸ DRD3 P35462 1/20 0.34
▸ KCNH2 Q12809 1/20 0.34
▸ ALOX15 P16050 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23116381 1.00 MGLL (0.39) MGLLALDH1A1MAPTNPSR1SMN1; SMN2
SCHEMBL22729795 0.91 MGLL (0.41) MGLLALDH1A1MAPTNPSR1SMN1; SMN2
SCHEMBL22729492 0.91 MGLL (0.40) MGLLALDH1A1MAPTNPSR1SMN1; SMN2
SCHEMBL29839364 0.91 MGLL (0.40) MGLLALDH1A1MAPTNPSR1SMN1; SMN2
SCHEMBL22729774 0.91 ALDH1A1 (0.35) MGLLALDH1A1MAPTNPSR1SMN1; SMN2
SCHEMBL23116409 0.89 MGLL (0.39) MGLLALDH1A1MAPTNPSR1SMN1; SMN2
SCHEMBL23116391 0.89 MGLL (0.41) MGLLALDH1A1MAPTNPSR1SMN1; SMN2
SCHEMBL22729791 0.89 GRIN2B (0.39) MGLLALDH1A1DRD2DRD3KCNH2
SCHEMBL22729578 0.88 MGLL (0.39) MGLL
SCHEMBL22729482 0.88 MGLL (0.39) MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11459325-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-10-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11459325-B2 Heterocyclic compound GBA1, GBA2, GALC MGLL 91/4885ALDH1A1 2660/4885MAPT 364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback